LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its ...
LAVA Therapeutics N.V. is a clinical-stage biotechnology company headquartered in Utrecht, the Netherlands. Founded in 2016, the company focuses on the development of bispecific antibodies, known as Gammabodies, which are engineered to engage and harness the therapeutic potential of gamma-delta T cells to combat cancer. The company's unique technology platform ...LAVA Therapeutics N.V. is a clinical-stage biotechnology company headquartered in Utrecht, the Netherlands. Founded in 2016, the company focuses on the development of bispecific antibodies, known as Gammabodies, which are engineered to engage and harness the therapeutic potential of gamma-delta T cells to combat cancer. The company's unique technology platform allows for the targeted activation of these specific immune cells, aiming to overcome the limitations of traditional cancer therapies.
LAVA's clinical pipeline includes several innovative candidates. Its lead program, LAVA-051, is currently undergoing Phase 1/2a clinical trials for the treatment of hematologic malignancies such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Additionally, the company is developing LAVA-1207, which targets metastatic castration-resistant prostate cancer. The pipeline is further supported by preclinical assets like LAVA-1223, LAVA-1266, and LAVA-1278, which are designed for various solid tumors and blood cancers.
From a financial and business perspective, LAVA is in the clinical development phase, which implies high research and development expenditures and no significant product revenue, typical for a biotechnology firm of its size. The company maintains a strong focus on capital efficiency, evidenced by its strategic partnerships, including a collaboration and licensing agreement with Janssen Biotech, Inc. to develop multi-specific antibody therapies.
Leadership is provided by CEO Steve Hurly, who brings extensive experience in building innovative biotechnology companies. The organizational structure is lean, with approximately 34 full-time employees operating across facilities in the Netherlands and the United States. As a publicly traded entity on the NASDAQ, LAVA faces the typical challenges of the biotech industry, including the need for continuous clinical success to maintain valuation, as indicated by its current status of operating in a development-intensive environment with significant investment in R&D and SG&A relative to its revenue profile. The company's goal remains the transformation of cancer therapy through its specialized, proprietary Gammabody platform.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$12.0M
+77.0%
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-25.1M
+40.0%
+16.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
+105.9%
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-247.8%
+61.3%
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-209.6%
+66.1%
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-19.6M
+52.3%
+64.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-163.3%
+73.0%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
19.0%
+54.3%
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.40x
-33.5%
+13.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
